CAPRICOR THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $22.3M | $25.2M | $2.6M | $244,898 |
| Research and development | $84.5M | $50.0M | $36.4M | $21.8M | $13.6M |
| Operating expenses | $108.1M | $64.8M | $49.3M | $32.2M | $21.2M |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M | -$20.9M |
| Interest expense | $3.0M | $0 | — | — | — |
| Pretax income | -$105.0M | -$40.5M | — | — | — |
| Income tax expense | $1,600 | $1,600 | — | — | — |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M | -$20.0M |
| Balance Sheet | |||||
| Cash and equivalents | $287.8M | $11.3M | $14.7M | $9.6M | $34.9M |
| Current assets | $322.9M | $163.4M | $50.9M | $42.9M | $36.4M |
| Total assets | $355.9M | $170.5M | $58.7M | $50.1M | $41.3M |
| Current liabilities | $35.8M | $21.0M | $31.3M | $23.6M | $4.1M |
| Total liabilities | $50.2M | $25.0M | $36.1M | $38.3M | $10.0M |
| Stockholders' equity | $305.8M | $145.5M | $22.6M | $11.8M | $31.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M |
| Depreciation and amortization | $1.9M | $1.4M | $1.1M | $533,131 | $245,697 |
| Stock-based compensation | $17.2M | $9.8M | $7.4M | $4.5M | $3.0M |
| Capital expenditure | $2.9M | $1.2M | $1.3M | $2.0M | $1.2M |
| Free cash flow | -$72.7M | -$41.2M | -$26.9M | $2.9M | -$18.0M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 57.9M · Free float 42.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.